From:  It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
 

Immune checkpoint inhibitors + EGFR-TKI therapy

Study nameSettingDrugsPhaseEfficacyAEsReferences
CheckMate012≥ 2ndNivolumab and erlotinibIbORR 15%, DCR 65%, PFS: 5.1 monthsG3: 24%, no G4 or G5 TRAEs[49]
TATTON≥ 2ndDurvalumab + osimertinibIbORR 43%≥ G3: 48%; ILD occurred in 22% (≥ G3, 8.7%)[14]
CAURAL≥ 2ndDurvalumab + osimertinibIIIORR 64% in the combination armNot sufficient data, grade 2 interstitial lung disease occurred in 1 patient.[46]
NCT020400642ndTremelimumab and gefitinibIPFS of 2.2 monthsG3 TRAE 81%[50]
NCT019981261stIpilimumab and erlotinibIPFS 27.8 monthsFour of the 11 patients had G3 colitis.[51]
NCT020132191st and anyAtezolizumab + erlotinibIbPFS 15.4 monthsG3 46%, no G4 or G5 TRAE.[52]
KEYNOTE 0211stPembrrolizumab + gefitinib (cohort F), Pembrrolizumab + erlotinib (cohort E)Phase I/IIORR 41.7% in cohort F and 14.3% in cohort EG3: 33.3% in cohort F, G3–4: 71.4% in cohort E[44]
Return to article view

ORR: objective response rate; DCR: dacryocystorhinostomy; PFS: progression free survival; TRAEs: treatment related adverse event; ILD: interstitial lung disease; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor